Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deal Watch: Genzyme Validates Alnylam's Strategy By Partnering On Hemophilia Candidate

Executive Summary

Astellas/Chromocell pain therapy collaboration centers on New Jersey biotech's platform technology, which may solve the problem of reproducing Nav1.7 receptors for in vitro assays. Xoma signs preclinical immuno-oncology partnership with Novartis, dimming the focus on Phase III flop for gevokizumab.

You may also be interested in...



Video: Interview With Baiju Shah Of BioMotiv

In an interview at the recent BioPharm America conference, Shah explains the role that BioMotiv, a self-described accelerator, plays in advancing academic research into private-sector biopharma companies.

Biogen Gives Up On Gosuranemab After No Benefit Seen In Alzheimer's Study

Biogen’s investigational anti-tau antibody gosuranemab has missed its primary efficacy endpoint in a Phase II study in patients with Alzheimer's disease, prompting the end of the trial and termination of the compound’s further clinical development.

Novel CAR-T Start-Up Mnemo Bags €75m Series A Financing

Mnemo Therapeutics’ promise in chimeric antigen receptor (CAR) T-cell therapy technologies allowed it to raise €75m in a series A financing round and the French biotech’s CEO tells Scrip he aims to raise yet more money in coming months to fund its development plans.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS057188

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel